Track topics on Twitter Track topics that are important to you
Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The companyâs products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladonâs first product candidate, MYDICARÂ®, delivers the gene for the SERCA2a enzyme and is currently being tested in Phase 1 and 2 clinical trials. Celladon is also developing traditional small molecule activators of SERCA2a for the treatment of heart failure. To learn more about Celladon, visit Celladonâs website at www.celladon.net.
2223 Avenida de la Playa #206
United States of America
LAVAL, QUEBEC -- (Marketwired) -- 07/07/17 -- Savaria Corporation (TSX: SIS) ("Savaria" or the "Corporation"), one of North America's leaders in the accessibility industry, is pleased to announce th...
TORONTO, ONTARIO -- (Marketwired) -- 08/16/17 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSX VENTURE: VPT) announces that at its Annual General Meeting on August 14, 2017 ...
REHOVOT, Israel, Oct. 18, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disor...
REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) diso...
CARLSBAD, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies...
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/11/17 -- Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to report that it has co...
CARLSBAD, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage ...
Celladon Corp., based in La Jolla, Calif., was launched in October 2004 as a privately held biotechnology company with the goal of becoming the leader in developing molecular therapies for the treatme...
Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in develop...
Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...
Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...
NEC Corporation of America (NEC) is a leading technology integrator providing solutions that improve the way people work and communicate. NEC delivers integrated Solutions for Soc...
We have published hundreds of Celladon Corporation news stories on BioPortfolio along with dozens of Celladon Corporation Clinical Trials and PubMed Articles about Celladon Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celladon Corporation Companies in our database. You can also find out about relevant Celladon Corporation Drugs and Medications on this site too.
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...